BioSpace

ESMO 2026: J&J delivers ‘immaculate’ early data for prostate cancer drug from Halda

JNJ-6143, which came from Johnson & Johnson’s $3 billion takeover of Halda Therapeutics in 2025, showed a 75% overall response rate in the Phase 1 readout.

By BioSpace

1 min read
ESMO 2026: J&J delivers ‘immaculate’ early data for prostate cancer drug from Halda
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights